Adjunctive nutraceuticals with standard pharmacotherapies in bipolar disorder: a systematic review of clinical trials
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Sarris J, Mischoulon D, Schweitzer I. Adjunctive nutraceuticals with standard pharmacotherapies in bipolar disorder: a systematic review of clinical trials. Bipolar Disord 2011: 13: 454–465. © 2011 The Authors. Journal compilation © 2011 John Wiley & Sons A/S. Objective: Studies using augmentation of pharmacotherapies with nutraceuticals in bipolar disorder (BD) have been conducted and preliminary evidence in many cases appears positive. To date, however, no specialized systematic review of this area has been conducted. We present the first systematic review of clinical trials using nutrient‐based nutraceuticals in combination with standard pharmacotherapies to treat BD. A subsequent aim of this report was to discuss posited underlying mechanisms of action. Methods: PubMed, CINAHL, Web of Science, and Cochrane Library databases, and grey literature were searched during mid‐2010 for human clinical trials in English using nutraceuticals such as omega‐3, N‐acetyl cysteine (NAC), inositol, and vitamins and minerals, in combination with pharmacotherapies to treat bipolar mania and bipolar depression. A review of the results including an effect size analysis (Cohen’s d) was subsequently conducted. Results: In treating bipolar depression, positive evidence with large effect sizes were found for NAC (d = 1.04) and a chelated mineral and vitamin formula (d = 1.70). On the outcome of bipolar mania, several nutraceuticals reduced mania with strong clinical effects: a chelated mineral formula (d = 0.83), L‐tryptophan (d = 1.47), magnesium (d = 1.44), folic acid (d = 0.40), and branched‐chain amino acids (d = 1.60). Mixed, but mainly positive, evidence was found for omega‐3 for bipolar depression, while no evidentiary support was found for use in mania. No significant effect on BD outcome scales was found for inositol (possibly due to small samples). Conclusions: BD treatment outcomes may potentially be improved by additional use of certain nutraceuticals with conventional pharmacotherapies. However, caution should be extended in interpreting the large effects of several isolated studies, as they have not yet been replicated in larger trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., Mackinnon, A., McGorry, P. D., & Berger, G. E. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.192 · Cited by 896
Omega 3 Fatty Acids in Bipolar Disorder: A Preliminary Double-blind, Placebo-Controlled Trial
Stoll, A. L., Severus, W. E., Freeman, M. P., Rueter, S., Zboyan, H. A., Diamond, E., Cress, K. K., & Marangell, L. B. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.5.407 · Cited by 814
Liu, S., Manson, J. E., Buring, J. E., Stampfer, M. J., Willett, W. C., & Ridker, P. M. (2002) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/75.3.492 · Cited by 594
Berk, M., Copolov, D. L., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., & Bush, A. I. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.022 · Cited by 500
Jordan, S. A., Cunningham, D. G., & Marles, R. J. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.12.005 · Cited by 415 · cited 1×
“Epigenetic studies are already demonstrating that nutraceutical combinations can trigger the expression of additional genes beyond the effect of their isolated nutraceutical components (potentially by altered modification histone and DNA methylation) (20).”
BackgroundN -acetylcysteine for antioxidant therapy: pharmacology and clinical utility
Dodd, S., Dean, O., Copolov, D. L., Malhi, G. S., & Berk, M. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14728220802517901 · Cited by 413
Appleton, K. M., Rogers, P. J., & Ness, A. R. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28313 · Cited by 353
Frangou, S., Lewis, M., & McCrone, P. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.188.1.46 · Cited by 309
Keck, P. E., Mintz, J., McElroy, S. L., Freeman, M. P., Suppes, T., Frye, M. A., Altshuler, L. L., Kupka, R., Nolen, W. A., Leverich, G. S., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.056 · Cited by 234 · cited 15×
“(DHA 1560 mg/day and EPA 360 mg/day) and found significantly reduced clinician-rated depression and mania scores from baseline.”
BackgroundInfluentialRoiser, J. P., McLean, A., Ogilvie, A. D., Blackwell, A. D., Bamber, D. J., Goodyer, I., Jones, P. B., & Sahakian, B. J. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300659 · Cited by 96 · cited 1×
“The activity of these branched chain amino acids may be due to competitive inhibition of phenylalanine and tyrosine which are involved in dopamine production (11, 38).”
Background
Research works printed but not linked: 56
- Suppes T, 2005, Challenges in the management of bipolar depression, J Clin Psychiatry, 66, 11
- 10.1002/jclp.20333 · DOI
- 10.1146/annurev.clinpsy.2.022305.095332 · DOI · Paper page
- 10.1159/000091771 · DOI · Paper page
- 10.1208/ps050325 · DOI · Paper page
- 10.1016/j.ogc.2009.10.005 · DOI
- 10.1111/j.1753-4887.2009.00180.x · DOI · Paper page
- 10.4088/JCP.v62n1204 · DOI · Paper page
- 10.1037/0033-2909.133.5.747 · DOI · Paper page
- 10.4088/JCP.v62n1203 · DOI · Paper page
- 10.1192/bjp.182.3.210 · DOI · Paper page
- 10.1007/s00406-007-0711-9 · DOI
- 10.1016/j.jpsychires.2008.06.003 · DOI
- Tassoni D, 2008, The role of eicosanoids in the brain, Asia Pac J Clin Nutr, 17, 220
- 10.1016/j.plefa.2006.07.009 · DOI
- 10.2174/1874467210902020207 · doi:10.2174/1874467210902020207 · Paper page
- 10.1016/0278-5846(90)90099-3 · DOI
- 10.1016/j.phymed.2009.04.001 · DOI
- Cohen J, 1988, Statistical Power Analyses for the Behavioral Sciences
- 10.4088/JCP.v66n1219b · DOI · Paper page
- 10.1038/ejcn.2008.81 · DOI
- 10.4088/JCP.v66n0608 · DOI · Paper page
- 10.1111/j.1399-5618.2010.00799.x · DOI
- 10.1111/j.2044-8341.1959.tb00467.x · DOI · Paper page
- 10.1192/bjp.133.5.429 · DOI · Paper page
- 10.1177/0269881106067787 · DOI · Paper page
- Hirashima F, 2004, Omega‐3 fatty acid treatment and T(2) whole brain relaxation times in bipolar disorder, Am J Psychiatry, 161, 1922, 10.1176/ajp.161.10.1922 · DOI · Paper page
- 10.1097/MCO.0b013e328336b615 · DOI
- 10.1038/sj.mp.4001887 · DOI · Paper page
- 10.1016/j.plefa.2006.07.005 · DOI · Paper page
- 10.1192/bjp.134.4.382 · DOI · Paper page
- 10.1016/0006-3223(85)90026-5 · DOI
- Bell CJ, 2005, Acute tryptophan depletion. Part II: clinical effects and implications, Aust N Z J Psychiatry, 39, 565, 10.1080/j.1440-1614.2005.01628.x · DOI · Paper page
- 10.1016/j.smrv.2010.04.001 · DOI · Paper page
- 10.1034/j.1399-5618.2000.020107.x · DOI · Paper page
- 10.1111/j.1399-5618.2006.00303.x · DOI · Paper page
- 10.1016/S0165-1781(99)00116-X · DOI
- Poleszak E, 2008, Benzodiazepine/GABA(A) receptors are involved in magnesium‐induced anxiolytic‐like behavior in mice, Pharmacol Rep, 60, 483
- 10.1016/j.mehy.2006.01.047 · DOI · Paper page
- 10.1016/0165-0327(86)90043-1 · DOI
- Beck A, 1987, The Beck Depression Inventory
- 10.1111/j.1600-0447.2009.01368.x · DOI · Paper page
- 10.1176/ajp.2007.164.6.861 · DOI · Paper page
- 10.1080/07315724.2009.10719785 · DOI · Paper page
- 10.1016/j.plefa.2006.07.003 · DOI
- 10.1111/j.1399-5618.2007.00386.x · DOI · Paper page
- 10.1016/j.jad.2010.09.004 · DOI · Paper page
- 10.1016/S0306-4522(02)00123-9 · DOI · Paper page
- 10.1016/j.jacc.2004.03.039 · DOI · Paper page
- 10.1176/appi.ajp.2009.09060881 · DOI · Paper page
- 10.1016/j.euroneuro.2006.11.006 · DOI · Paper page
- 10.1176/appi.ajp.160.5.996 · DOI · Paper page
- 10.4088/JCP.v64n0317d · DOI
- 10.1016/0006-3223(95)00423-8 · DOI
- 10.1016/S0165-1781(99)00107-9 · doi:10.1016/s0165-1781(99)00107-9
- 10.1176/ajp.139.9.1162 · DOI · Paper page
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Oxidative Stress and the Central Nervous System
Salim, S. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.237503 · Cited by 1,247
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“, 2008a) and other nutraceuticals (Sarris et al., 2011) may also be considered.”
BackgroundInfluentialOxidative Stress and Psychological Disorders
Salim, S. (2014) · Current Neuropharmacology · doi:10.2174/1570159x11666131120230309 · Cited by 557
Nutritional psychiatry: The present state of the evidence
Marx, W., Moseley, G., Berk, M., & Jacka, F. (2017) · Proceedings of the Nutrition Society · doi:10.1017/s0029665117002026 · Cited by 469
Metadata
- Authors
- Sarris, J., Mischoulon, D., & Schweitzer, I.
- Venue
- Bipolar Disorders
- Publisher
- Wiley
- Published
- 2011-08
- Volume
- 13
- Issue
- 5-6
- Pages
- 454-465
- ISSN
- 1398-5647 (ISSN-L)
- 1399-5618
- OpenAlex
- W1959849744
- Cited by
- 78
- References
- 10
- FWCI
- 0.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adjunctive nutraceuticals with standard pharmacotherapies in bipolar disorder: a systematic review of clinical trials. https://app.cochat.ai/papers/10.1111/j.1399-5618.2011.00945.x
- The paper
- Sarris, J., Mischoulon, D., & Schweitzer, I. (2011). Adjunctive nutraceuticals with standard pharmacotherapies in bipolar disorder: a systematic review of clinical trials. Bipolar Disorders. https://doi.org/10.1111/j.1399-5618.2011.00945.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.